Business Summary
|
Resverlogix Corp. is a biotechnology company engaged in the discovery and development of pharmaceuticals. It has developed three separate programs in the cardiovascular disease (CVD) area of research. The primary CVD program, NexVas Plaque Regression (NexVas PR), is a technology platform for the development of drugs that enhance ApolipoproteinA-I (ApoA-l). NexVas Vascular Inflammation (NexVas VI), its second CVD program, is focuses on the development of drugs that target molecular markers of inflammation. ReVas, its third cardiovascular program, is focused on the development of therapeutics to be used with medical devices for the treatment of cardiovascular diseases. NexVas Alzheimer’s Disease (NexVas AD) is a clinical stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of beta amyloid plaque. TGF-ßeta Shield (TGF-ß Shield) is focused on the treatment for grievous proliferative diseases, such as cancer and fibrotic conditions.
| | (Source: ARS)
|
|
|
